Ivax appoints new head; Debregeas and Le Portz get on board
This article was originally published in Clinica
Executive Summary
Miami, Florida-based IVAX Diagnostics has appointed pharmaceutical industry veteran Paul Kennedy as CEO, president and chairman. Mr Kennedy has held senior executive positions at Novo Nordisk France, Abbot France and UK health retailer Boots. He was most recently at Cozart, the UK drugs-of-abuse testing company that was bought by Concateno in October 2007, where he established and grew the company's international sales. In conjunction with Mr Kennedy's appointment, IVAX announced that Patrice Debregeas – one of the two entrepreneurs that bought a major stake in IVAX last month (see Clinica No 1323, p 18) -- is to become vice-chairman. Seasoned healthcare investor Laurent Le Portz will also join the board of directors and IVAX's audit and compensation committees.